A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03400332 |
|
Recruitment Status :
Recruiting
First Posted : January 17, 2018
Last Update Posted : May 11, 2021
|
Sponsor:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Bristol-Myers Squibb
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cancer | Drug: BMS-986253 Biological: Nivolumab Biological: Ipilimumab Other: Placebo | Phase 1 Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 372 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers |
| Actual Study Start Date : | February 12, 2018 |
| Estimated Primary Completion Date : | February 28, 2023 |
| Estimated Study Completion Date : | June 8, 2024 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
| Experimental: Part 1A: BMS-986253 + nivolumab |
Drug: BMS-986253
Specified dose on specified days Biological: Nivolumab Specified dose on specified days
Other Names:
|
| Experimental: Part 1B: BMS-986253 + nivolumab |
Drug: BMS-986253
Specified dose on specified days Biological: Nivolumab Specified dose on specified days
Other Names:
|
| Experimental: Part 1C: BMS-986253 + nivolumab + ipilimumab |
Drug: BMS-986253
Specified dose on specified days Biological: Nivolumab Specified dose on specified days
Other Names:
Biological: Ipilimumab Specified dose on specified days
Other Names:
|
| Experimental: Part 2A: BMS-986253 + nivolumab + ipilimumab |
Drug: BMS-986253
Specified dose on specified days Biological: Nivolumab Specified dose on specified days
Other Names:
Biological: Ipilimumab Specified dose on specified days
Other Names:
|
| Placebo Comparator: Part 2B: Placebo + nivolumab + ipilimumab |
Biological: Nivolumab
Specified dose on specified days
Other Names:
Biological: Ipilimumab Specified dose on specified days
Other Names:
Other: Placebo Specified dose on specified days |
Primary Outcome Measures :
- Incidence of adverse events (AE) [ Time Frame: Approximately 5 years ]Part 1
- Incidence of serious adverse events (SAE) [ Time Frame: Approximately 5 years ]Part 1
- Incidence of AEs meeting protocol-defined dose limiting toxicities (DLT) criteria [ Time Frame: Approximately 5 years ]Part 1
- Incidence of AEs leading to discontinuation [ Time Frame: Approximately 5 years ]Part 1
- Incidence of deaths [ Time Frame: Approximately 5 years ]Part 1
- Incidence of clinically significant changes in clinical laboratory results: Hematology tests [ Time Frame: Approximately 5 years ]Part 1
- Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests [ Time Frame: Approximately 5 years ]Part 1
- Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests [ Time Frame: Approximately 5 years ]Part 1
- Progression-free survival (PFS) hazard ratio based on Blinded independent central review (BICR) assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [ Time Frame: Approximately 5 years ]Part 2, participants with advanced melanoma, selected by baseline serum interleukin-8 (IL-8) level using RECIST v1.1
Secondary Outcome Measures :
- Objective response rate (ORR) based on Blinded independent central review (BICR) assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [ Time Frame: Approximately 5 years ]Part 1 and Part 2
- Median duration of response (mDOR) per response evaluation criteria in solid tumors (RECIST) v1.1 [ Time Frame: Approximately 5 years ]Part 1
- Incidence of anti-drug antibody (ADA) to BMS-986253 [ Time Frame: Approximately 5 years ]Part 1 and Part 2
- Serum biomarker concentration [ Time Frame: Approximately 5 years ]Part 1
- Maximum observed serum concentration (Cmax) [ Time Frame: Approximately 5 years ]Part 1 and Part 2
- Time of maximum observed serum concentration (Tmax) [ Time Frame: Approximately 5 years ]Part 1 and Part 2
- Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] [ Time Frame: Approximately 5 years ]Part 1 and Part 2
- Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)] [ Time Frame: Approximately 5 years ]Part 1 and Part 2
- Observed serum concentration at the end of a dosing interval (CTAU) [ Time Frame: Approximately 5 years ]Part 1 and Part 2
- Trough observed serum concentration at the end of the dosing interval (CTROUGH) [ Time Frame: Approximately 5 years ]Part 1 and Part 2
- Progression-free survival (PFS) hazard ratio based on Blinded independent central review (BICR) assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [ Time Frame: Approximately 5 years ]Part 2, participants with advanced melanoma, using RECIST v1.1 (regardless of baseline serum IL-8 levels)
- Overall Survival (OS) [ Time Frame: Approximately 5 years ]Part 2
- Incidence of AEs [ Time Frame: Approximately 5 years ]Part 2
- Incidence of SAEs [ Time Frame: Approximately 5 years ]Part 2
- Incidence of AEs leading to discontinuation [ Time Frame: Approximately 5 years ]Part 2
- Incidence of death [ Time Frame: Approximately 5 years ]Part 2
- Incidence of clinically significant changes in clinical laboratory results: Hematology tests [ Time Frame: Approximately 5 years ]Part 2
- Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests [ Time Frame: Approximately 5 years ]Part 2
- Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests [ Time Frame: Approximately 5 years ]Part 2
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent and/or unresectable) with measurable disease per RECIST v1.1
- At least 1 lesion accessible for biopsy
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
Exclusion Criteria:
- Participants with CNS metastases as the only site of active disease (Participants with controlled brain metastases; however, will be allowed to enroll)
- Participants with active, known or suspected autoimmune disease
- Participants with conditions requiring systemic treatment with either corticosteroids (> 10mg prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration
- Participants with a known history of testing positive for Human Immunodeficiency Virus (HIV) or known Acquired Immunodeficiency Syndrome (AIDS)
- Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy
Other protocol defined inclusion/exclusion criteria could apply
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03400332
Contacts
| Contact: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, | please email: | Clinical.Trials@bms.com | |
| Contact: First line of the email MUST contain NCT # and Site #. |
Locations
Show 54 study locations
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
| Study Director: | Bristol-Myers Squibb | Bristol-Myers Squibb |
Additional Information:
| Responsible Party: | Bristol-Myers Squibb |
| ClinicalTrials.gov Identifier: | NCT03400332 |
| Other Study ID Numbers: |
CA027-002 2018-000340-26 ( EudraCT Number ) |
| First Posted: | January 17, 2018 Key Record Dates |
| Last Update Posted: | May 11, 2021 |
| Last Verified: | May 2021 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Nivolumab Ipilimumab Antineoplastic Agents, Immunological |
Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action |